Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 397.41M P/E - EPS this Y -21.60% Ern Qtrly Grth -
Income -203.85M Forward P/E -3.30 EPS next Y 12.00% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.66 EPS next 5Y - 52W High Chg -44.00%
Recommedations 1.70 Quick Ratio 5.81 Shares Outstanding 80.03M 52W Low Chg 32.00%
Insider Own 1.21% ROA -51.20% Shares Float 55.45M Beta 0.83
Inst Own 113.86% ROE -121.29% Shares Shorted/Prior 16.62M/14.91M Price 7.32
Gross Margin - Profit Margin - Avg. Volume 331,548 Target Price 28.14
Oper. Margin - Earnings Date Nov 5 Volume 456,607 Change 6.86%
About Scholar Rock Holding Corporatio

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporatio News
11/15/24 Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13/24 Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
11/12/24 Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
11/04/24 Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
11/01/24 Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
10/31/24 Scholar Rock to Participate in Upcoming Investor Conferences
10/31/24 Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
10/22/24 Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
10/21/24 Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
10/11/24 PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors
10/09/24 Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ...
10/09/24 Here's Why Everybody's Talking About Scholar Rock Right Now
10/08/24 Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
10/08/24 SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
10/08/24 Scholar Rock’s SMA Treatment Trials Show Promising Results
10/08/24 Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says
10/08/24 Scholar Rock stocks skyrocket after SMA drug scores at Phase III
10/07/24 Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy
10/07/24 Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/07/24 Scholar Rock Shares Quadruple On Positive Drug-Study Results
SRRK Chatroom

User Image tttggg Posted - 3 days ago

@Oknrv I think you misinterpreted her point. She tried to make a case for $ARWR $WVE, not $SRRK.

User Image IN0V8 Posted - 3 days ago

$SRRK Opportunity BMO raises target price to $39 from $38 H.C. Wainwright raises PT to $40 from $35 Raymond James ups target price to $39 from $30

User Image Muffinsss Posted - 3 days ago

$SRRK think biohaven will report their findings on a Friday?. ruin the weekend for their holders as these companies like to do with bad news. Maybe they learned that trick from office space. they have other successful things in their pipeline so damage shouldnt be that bad for them

User Image swingingtech Posted - 4 days ago

$WGO $LNG $SRRK https://wallstreetwaves.com/significant-tuesday-options-movements-wgo-lng-srrk/

User Image greenmachine1 Posted - 4 days ago

$SRRK slow bleed all week.

User Image greenmachine1 Posted - 4 days ago

$SRRK what a bullshit upgrade on shit tastic earnings

User Image DankPotentialBuckz Posted - 4 days ago

$SRRK puts printed, again. Easy money every time shorting inflated crap like this ✌️

User Image DankPotentialBuckz Posted - 4 days ago

$SRRK that’s cute, reported “earnings”

User Image greenmachine1 Posted - 4 days ago

$SRRK let’s fill that gap down to $7 where it should be. $0 revenue deserves to be punished

User Image greenmachine1 Posted - 4 days ago

$SRRK $0 revenue for Q3…. Time to put this to bed

User Image briefingcom Posted - 4 days ago

$SRRK: Scholar Rock misses by $0.08 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241112071054SRRK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Chief1912 Posted - 4 days ago

$SRRK long road to approval, build out team, build out relationship with doctors. Discussions with regulators at early stage. Will need more cash unfortubarely. Dilution.

User Image greenmachine1 Posted - 4 days ago

$SRRK how is the stock not reacting to bad earnings?

User Image WineauxInBordeaux Posted - 1 week ago

@xyed666 depends. If $SAVA goes the buy-out route, unlikely. If they decide to go it alone, they will need a couple of hundred million to build the infrastructure. Look at $SRRK as an example.

User Image Chief1912 Posted - 1 week ago

$SRRK

User Image ahab Posted - 1 week ago

$CORT 48.06 10/23/24 3 red day price level, $RNA 45.42 3 red day price level, < WINNERS. $SRRK 3red day price level , down 2-3 % going stone age stock picking on this sector

User Image windough Posted - 1 week ago

$SRRK a break below 2510

User Image SkSk_ Posted - 2 weeks ago

$SRRK wow, Cowen has the BHVN SMA data as a +75%/-50% binary for SRRK. I think those numbers are probably aggressive but should be very volatile for both stocks nonetheless. not sure why bears here think ER will be a negative catalyst for SRRK. every tute invested here is aware its a pre-rev biotech. by that logic, every pre-rev biotech with multibillion valuation is a short? (CYTK, RVMD, BBIO, RNA, JANX, literally endless list) if you're short here, you're betting on BHVN hitting their readout and taking future market share. No position yet, need to do more work on BHVN PoS.

User Image Chief1912 Posted - 2 weeks ago

$SRRK New month. Which one of these MM will break character and sell first. Thats the one that will make alot of money and still have a job.

User Image Joe32141 Posted - 10/31/24

$SRRK 20????

User Image Bromberger Posted - 10/31/24

$SRRK don’t be affraid, my bears 😉

User Image Chief1912 Posted - 10/31/24

$SRRK

User Image btb2025 Posted - 10/31/24

$CAPR $CEG $SRRK some of these recent multi baggers need to cool off a bit imo as it gained huge for past couple of months without any pullback

User Image WillisC Posted - 10/29/24

$SRRK I also think over inflated. It keeps rising on low volume. Wait for break down then take short position. Maybe after earnings

User Image DankPotentialBuckz Posted - 10/29/24

$SRRK doing a deep dive, this company literally has no revenues or sales for years. It’s literally a $2.7 billion science fair project. Bought more puts today.

User Image Bleu7141 Posted - 10/29/24

$SRRK 15% of all volume yesterday and 20% today traded in the last second of normal hours - 214K purchase today at close. Somebody knows something or again the manipulation is strong with this one.

User Image Capitulation_0 Posted - 10/29/24

$IBIO early early early but looking at $SRRK.

User Image wallstreetcorruption Posted - 10/28/24

$SRRK easy takeover target , only company that prevents muscle loss drug on GLP1 ‘s

User Image Bleu7141 Posted - 10/28/24

$SRRK shorted at open just to wait all day to break even. Broker held 400% margin so I couldn't make any other trades or short more at HOD - % margin requirement seems excessive?

User Image certus11 Posted - 10/28/24

$SRRK SI reduced by 2% and now sits at 16.53%. This makes one wonder if it's sell side having strong conviction or they are trapped in.

Analyst Ratings
BMO Capital Outperform Aug 9, 24
HC Wainwright & Co. Buy Jun 25, 24
BMO Capital Outperform Jun 13, 24
HC Wainwright & Co. Buy Jun 4, 24
HC Wainwright & Co. Buy May 23, 24
HC Wainwright & Co. Buy May 8, 24
Truist Securities Buy Apr 3, 24
Raymond James Strong Buy Mar 28, 24
Piper Sandler Overweight Mar 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Myles Edward H COO & CFO COO & CFO Dec 29 Sell 19.16 12,459 238,714 168,784 12/29/23
Myles Edward H COO & CFO COO & CFO Dec 29 Option 4.86 12,459 60,551 181,243 12/29/23
Qatanani Mo SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH Dec 14 Sell 18.18 24,662 448,355 80,818 12/15/23
Qatanani Mo SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH Dec 14 Option 10 8,437 84,370 105,480 12/15/23
Myles Edward H COO & CFO COO & CFO Nov 02 Sell 12.5129 35,007 438,039 168,784 11/03/23
AKKARAJU SRINIVAS Director Director Oct 16 Buy 6.85 2,189,781 15,000,000 6,788,609 10/18/23
Samsara BioCapital GP, LLC 10% Owner 10% Owner Oct 16 Buy 6.85 2,189,781 15,000,000 6,788,609 10/18/23
Invus Public Equities, L.P. Director Director Oct 12 Buy 7.7 2,199,931 16,939,469 11,259,438 10/16/23
Qatanani Mo SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH Sep 18 Sell 6.34 1,945 12,331 97,043 09/20/23
Invus Public Equities, L.P. 10% Owner 10% Owner Apr 28 Buy 6.4279 31,557 202,845 9,059,507 05/02/23
Invus Public Equities, L.P. 10% Owner 10% Owner Jan 09 Sell 9.482 1,094 10,373 9,027,950 01/11/23
Myles Edward H Chief Financial Offi.. Chief Financial Officer Nov 11 Sell 35.12 78,301 2,749,931 24,150 11/15/21